US Patent

US8129362 — Combination/association of adapalene and benzoyl peroxide for treating acne lesions

Method of Use · Assigned to Galderma Research and Development SNC · Expires 2027-07-18 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a daily topical regimen using a combination of adapalene and benzoyl peroxide to treat and reduce acne lesions.

USPTO Abstract

Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).

Drugs covered by this patent

Differin (ADAPALENE) · Galderma Labs Lp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1078`	—	Differin

Patent Metadata

Patent number: US8129362
Jurisdiction: US
Classification: Method of Use
Expires: 2027-07-18
Drug substance claim: No
Drug product claim: No
Assignee: Galderma Research and Development SNC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.